Medtronic (MDT) Set to Announce Earnings on Tuesday

Medtronic logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Medtronic is due to report Q2 2027 results before market open on November 24; analysts expect earnings of $1.33 per share and revenue of $9.48 billion. The company’s quarterly EPS guidance is $1.32–$1.34, with FY 2027 guidance of $5.94–$6.00.
  • In its most recent reported quarter, Medtronic beat consensus with EPS of $1.45 and revenue of $9.76 billion; revenue rose 13.7% year over year.
  • Medtronic plans to acquire Contego Medical for $380 million, expanding its vascular portfolio with treatments for carotid artery disease and peripheral thrombectomy.
  • Interested in Medtronic? Here are five stocks we like better.

Medtronic (NYSE:MDT - Get Free Report) is expected to be posting its Q2 2027 results before the market opens on Tuesday, November 24th. Analysts expect Medtronic to post earnings of $1.33 per share and revenue of $9.48 billion for the quarter. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Interested persons can check the company's upcoming Q2 2027 earnings summary page for the latest details on the call scheduled for Tuesday, November 24, 2026 at 7:30 AM ET.

Medtronic (NYSE:MDT - Get Free Report) last issued its quarterly earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.39 by $0.06. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. The business had revenue of $9.76 billion for the quarter, compared to the consensus estimate of $9.55 billion. During the same period in the prior year, the firm posted $1.26 earnings per share. The business's quarterly revenue was up 13.7% on a year-over-year basis. On average, analysts expect Medtronic to post $5.98 EPS for the current fiscal year and $6.35 EPS for the next fiscal year.

Medtronic Stock Performance

Shares of MDT opened at $102.92 on Tuesday. The company has a current ratio of 2.07, a quick ratio of 1.54 and a debt-to-equity ratio of 0.50. The firm has a market cap of $131.65 billion, a PE ratio of 17.66, a P/E/G ratio of 2.36 and a beta of 0.56. Medtronic has a 12 month low of $73.31 and a 12 month high of $106.33. The stock has a fifty day moving average price of $93.89 and a 200-day moving average price of $88.49.

Medtronic Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, October 16th. Investors of record on Friday, September 25th were given a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend was Friday, September 25th. Medtronic's dividend payout ratio is currently 70.94%.

Insiders Place Their Bets

In other Medtronic news, EVP Michael Marinaro sold 10,420 shares of the company's stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $96.00, for a total value of $1,000,320.00. Following the sale, the executive vice president directly owned 105,916 shares of the company's stock, valued at approximately $10,167,936. This represents a 8.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Geoffrey Martha sold 50,000 shares of the stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $95.00, for a total value of $4,750,000.00. Following the sale, the chief executive officer directly owned 277,866 shares in the company, valued at $26,397,270. This represents a 15.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 61,903 shares of company stock valued at $5,889,203. 0.27% of the stock is owned by insiders.

Key Stories Impacting Medtronic

These are some of the MDT stories that stood out recently:

  • Positive Sentiment: Medtronic plans to acquire privately held Contego Medical for $380 million. Contego develops treatments for carotid artery disease and peripheral thrombectomy; the deal would expand Medtronic’s vascular portfolio and build on an existing U.S. distribution partnership. Medtronic to buy Contego Medical for $380M
  • Negative Sentiment: Wall Street Zen lowered its rating on Medtronic shares, a potentially negative sentiment signal. The article listing does not specify the revised rating or rationale. Medtronic Stock Rating Lowered by Wall Street Zen

Analyst Upgrades and Downgrades

MDT has been the subject of a number of research analyst reports. Piper Sandler reiterated a "neutral" rating on shares of Medtronic in a research note on Wednesday, October 14th. Wells Fargo & Company boosted their price target on Medtronic from $102.00 to $104.00 and gave the stock an "overweight" rating in a research note on Wednesday, September 2nd. BTIG Research dropped their price target on Medtronic from $100.00 to $99.00 and set a "buy" rating on the stock in a research note on Monday, October 12th. Bank of America upped their price objective on shares of Medtronic from $95.00 to $110.00 and gave the company a "buy" rating in a report on Wednesday, September 2nd. Finally, UBS Group reaffirmed a "cautious" rating on shares of Medtronic in a research report on Wednesday, October 14th. Eighteen equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Medtronic presently has a consensus rating of "Moderate Buy" and an average price target of $102.88.

Check Out Our Latest Stock Report on Medtronic

Medtronic Company Profile

(Get Free Report)

Medtronic plc is a medical technology company that develops and manufactures devices and therapies for a range of health conditions. Its products include pacemakers and defibrillators, heart valves, surgical technologies, neurostimulation devices, and insulin pumps and other diabetes-management products. The company was founded in Minneapolis in 1949 by Earl Bakken and Palmer Hermundslie as a medical equipment repair business. It has since grown into a global company serving patients and health care providers in more than 150 countries.

Featured Stories

Earnings History for Medtronic (NYSE:MDT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Medtronic Right Now?

Before you consider Medtronic, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medtronic wasn't on the list.

While Medtronic currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines